Lucid Diagnostics (NASDAQ:LUCD) Cut to Sell at Wall Street Zen

Lucid Diagnostics (NASDAQ:LUCD) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

LUCD has been the topic of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Wednesday, November 5th. Ascendiant Capital Markets boosted their target price on Lucid Diagnostics from $7.75 to $8.00 and gave the stock a “buy” rating in a report on Monday, October 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a research note on Thursday. Finally, BTIG Research boosted their price objective on Lucid Diagnostics from $2.00 to $2.50 and gave the company a “buy” rating in a report on Friday, September 5th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $3.88.

Lucid Diagnostics Stock Performance

Shares of LUCD stock opened at $1.07 on Friday. The stock’s 50-day moving average is $1.13 and its two-hundred day moving average is $1.17. The firm has a market cap of $147.32 million, a price-to-earnings ratio of -1.03 and a beta of 1.22. Lucid Diagnostics has a 1 year low of $0.75 and a 1 year high of $1.80.

Lucid Diagnostics (NASDAQ:LUCD) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The business had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $1.35 million. As a group, research analysts predict that Lucid Diagnostics will post -0.84 EPS for the current year.

Insider Transactions at Lucid Diagnostics

In other Lucid Diagnostics news, Director Dennis Matheis bought 100,000 shares of Lucid Diagnostics stock in a transaction dated Wednesday, August 20th. The stock was bought at an average price of $1.02 per share, for a total transaction of $102,000.00. Following the completion of the acquisition, the director directly owned 665,443 shares of the company’s stock, valued at approximately $678,751.86. This trade represents a 17.69% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Berkshire Asset Management LLC PA acquired a new stake in Lucid Diagnostics during the first quarter valued at $30,000. Northwestern Mutual Wealth Management Co. acquired a new position in Lucid Diagnostics in the 1st quarter valued at $37,000. Quadrature Capital Ltd bought a new position in shares of Lucid Diagnostics in the second quarter worth about $29,000. Sprott Inc. acquired a new position in shares of Lucid Diagnostics during the third quarter worth approximately $25,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Lucid Diagnostics in the 1st quarter valued at $39,000. 74.01% of the stock is owned by hedge funds and other institutional investors.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.